EnWave Corp (TSX-V:ENW, OTC:NWVCF, FRA:E4U) earlier this week announced a new agreement involving Swiss Cannabis Selection and Schibano Pharma, marking another step in the company's renewed push into the cannabis processing sector.
Speaking with Proactive, chief executive Brent Charleton said interest in EnWave's technology has been increasing following the collection of commercial-scale operating data from licensed cannabis producers in Canada.
Power Metallic Mines Inc (TSX-V:PNPN, FRA:IVV1, OTCQB:PNPNF) is approaching an inflection point, according to analysts at Noble Capital Markets, with a strengthened treasury now enabling it to accelerate exploration and development at its flagship Nisk Project in Quebec while also pursuing opportunities in Saudi Arabia.
The analyst carries an Outperform rating on the stock, noting that Power Metallic continues to report encouraging drilling and metallurgical results that are expanding the scale and understanding of the Nisk-Lion-Tiger mineral system, supporting future mineral resource growth.
Snail Inc (NASDAQ:SNAL) presented at the Noble Virtual Conference on June 3, with CFO Heidi Chow and Senior Manager FP&A Peter Lin outlining the company's return to profitability, a packed 2026 release schedule, and progress on its digital assets strategy.
According to analysts at Noble, the presentation underscored the durability of the company's flagship ARK franchise, which has generated approximately $1 billion in revenue since launch, surpassed 113 million installs, and accumulated 4.4 billion hours of gameplay.
Three of the world’s most valuable private companies—SpaceX, Anthropic and OpenAI—are preparing to enter public markets in what could become one of the largest IPO waves in history. In this op-ed, Frank Holmes, CEO of U.S. Global Investors (NASDAQ:GROW), explores what these mega listings could mean for investors and index funds, warning that their scale may reshape portfolio construction, force major rebalancing across benchmarks and mark a turning point in how innovation flows from private markets into public ownership.
In case you’ve been living under a rock for the past few months, three of the world’s largest and most consequential private companies—SpaceX, Anthropic and OpenAI—are preparing to go public in the same year. Together, they could add nearly $4 trillion in market cap to public markets.
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF, FRA:1SS) will host a live shareholder update on June 25, with its executive team featuring a review of fourth-quarter results, audited financials for the fiscal year ended March 31, 2026, and a live Q&A session.
CEO Evan Gappelberg and CFO Anum Waqas will lead the livestream, covering the company's financial performance, strategy, and growth outlook.
Miivo Holdings Corp (TSX-V:MIVO) said its board of directors has approved a proposed name change to Miivo AI Inc.
The company said the new name better reflects its strategic focus on artificial intelligence technologies and solutions.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) said it will use Europe’s flagship allergy and clinical immunology congress to showcase progress across its pollen and food allergy pipeline, including clinical proof-of-concept data for its VLP Peanut candidate.
The AIM-listed biotechnology company will present 15 posters and oral presentations at the European Academy of Allergy and Clinical Immunology Congress 2026, which takes place in Istanbul, Türkiye, from 12 to 15 June.
Vitrafy Life Sciences Ltd (ASX:VFY, OTC:VFYLF) is raising A$30 million in an institutional placement, which will give it fresh capital to expand manufacturing capacity and accelerate commercial growth in the United States following recent progress in the US blood market.
The placement was strongly supported by new and existing institutional and sophisticated investors and will see the company issue around 11.5 million new shares at A$2.60 each.
Neurizon Therapeutics Ltd (ASX:NUZ, OTC:NUZTF, FRA:ECQ0) has reached a key milestone in the HEALEY ALS Platform Trial, with more than half of participants in the study’s NUZ-001 treatment arm now dosed ahead of schedule, reinforcing confidence in the program’s timeline and recruitment momentum.
The company said 129 of the planned 240 participants in Regimen I of the HEALEY ALS Platform Trial had received treatment as of 9 June 2026, while 167 participants had been assigned to the study arm. Recruitment is continuing across 78 activated clinical trial sites in the United States.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week announced that the US Food and Drug Administration (FDA) granted Fast Track Designation to its allogeneic CAR T therapy azer-cel for relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory marginal zone lymphoma (MZL), providing additional momentum for the company's cell therapy program.
Speaking with Proactive, managing director and chief executive officer Leslie Chong said the designation followed ongoing engagement with the FDA and reflected both the unmet medical need in these blood cancer indications and the clinical activity observed to date.
AuMEGA Metals Ltd (ASX:AAM, TSX:AUM, OTCQB:AUMMF, FRA:FRA: MA30) earlier this week announced the mobilisation of field crews to southwestern Newfoundland and Labrador, marking the start of a major 2026 exploration campaign that will lead into diamond drilling across priority targets on the Cape Ray Shear Zone.
Managing director and CEO Sam Pazuki told Proactive that the company had begun preparatory fieldwork ahead of drilling, which was delayed by persistent winter conditions across Newfoundland.
Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR)earlier this week announced a maiden JORC-compliant mineral resource estimate for the Leven Star Reef at its Belltopper Gold Project in Victoria, providing an initial resource foundation while highlighting the broader growth potential of the project.
The company reported an inferred mineral resource of 760,000 tonnes grading 3.6 g/t gold for 87,000 ounces of contained gold. The resource represents the first formal resource estimate at Belltopper and covers only one of at least eight identified gold-bearing reefs within the project area.